Cargando…
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255266/ https://www.ncbi.nlm.nih.gov/pubmed/22829166 http://dx.doi.org/10.1038/bcj.2011.20 |
| _version_ | 1782220971548082176 |
|---|---|
| author | Karlsson, C Dahl, H Lundin, J Rossmann, E Brytting, M Mellstedt, H Linde, A Österborg, A |
| author_facet | Karlsson, C Dahl, H Lundin, J Rossmann, E Brytting, M Mellstedt, H Linde, A Österborg, A |
| author_sort | Karlsson, C |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3255266 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-32552662012-01-11 Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia Karlsson, C Dahl, H Lundin, J Rossmann, E Brytting, M Mellstedt, H Linde, A Österborg, A Blood Cancer J Letter to the Editor Nature Publishing Group 2011-06 2011-06-10 /pmc/articles/PMC3255266/ /pubmed/22829166 http://dx.doi.org/10.1038/bcj.2011.20 Text en Copyright © 2011 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
| spellingShingle | Letter to the Editor Karlsson, C Dahl, H Lundin, J Rossmann, E Brytting, M Mellstedt, H Linde, A Österborg, A Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia |
| title | Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia |
| title_full | Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia |
| title_fullStr | Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia |
| title_full_unstemmed | Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia |
| title_short | Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia |
| title_sort | virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255266/ https://www.ncbi.nlm.nih.gov/pubmed/22829166 http://dx.doi.org/10.1038/bcj.2011.20 |
| work_keys_str_mv | AT karlssonc virusreactivationsandserologypatternsfollowingfirstlinetherapywithalemtuzumaborfludarabinebasedcombinationtherapyinpatientswithchroniclymphocyticleukemia AT dahlh virusreactivationsandserologypatternsfollowingfirstlinetherapywithalemtuzumaborfludarabinebasedcombinationtherapyinpatientswithchroniclymphocyticleukemia AT lundinj virusreactivationsandserologypatternsfollowingfirstlinetherapywithalemtuzumaborfludarabinebasedcombinationtherapyinpatientswithchroniclymphocyticleukemia AT rossmanne virusreactivationsandserologypatternsfollowingfirstlinetherapywithalemtuzumaborfludarabinebasedcombinationtherapyinpatientswithchroniclymphocyticleukemia AT bryttingm virusreactivationsandserologypatternsfollowingfirstlinetherapywithalemtuzumaborfludarabinebasedcombinationtherapyinpatientswithchroniclymphocyticleukemia AT mellstedth virusreactivationsandserologypatternsfollowingfirstlinetherapywithalemtuzumaborfludarabinebasedcombinationtherapyinpatientswithchroniclymphocyticleukemia AT lindea virusreactivationsandserologypatternsfollowingfirstlinetherapywithalemtuzumaborfludarabinebasedcombinationtherapyinpatientswithchroniclymphocyticleukemia AT osterborga virusreactivationsandserologypatternsfollowingfirstlinetherapywithalemtuzumaborfludarabinebasedcombinationtherapyinpatientswithchroniclymphocyticleukemia |